Zeta’s rabbit recombinant antibody recognizes GCDFP-15/PIP, an important protein marker for breast cancer, as it is found in approximately 50% of all breast cancer specimens. The GCDFP-15 antibody is useful in the identification of metastatic breast carcinoma, or fluid analysis, sometimes paired with Mammaglobin.
Zeta’s antibody to GCDFP-15 recognizes a prolactin and androgen-controlled protein of 15kDa, identified as Gross Cystic Disease Fluid Protein 15 (GCDFP-15) or Prolactin Inducible Protein (PIP). GCDFP-15 is a major protein component of benign breast gross cysts. GCDFP-15 is a known marker of breast cancer, as it is found in approximately 50% of all breast cancer specimens. The GCDFP-15 antibody is useful in the identification of metastatic breast carcinoma, or fluid analysis.
GCDFP-15 is a component of secretions from breast composed of several glycoproteins, and GCDFP-15 is considered to be a marker of apocrine differentiation. Numerous studies have shown GCDFP-15 (BRST -2) to be a specific marker for breast cancer in formalin-fixed paraffin-embedded tissues and in cytologic preparation (fine needle aspirates). Other types of tissues that express GCDFP-15 are axillary sweat glands and submandibular salivary glands.
GCDFP-15 is frequency used in concert with Mammaglobin (Mammaglobin Recombinant IVD Antibody – Zeta Corporation (zeta-corp.com), a mammary-specific member of the uteroglobin family, is known to be overexpressed in human breast cancer. Mammaglobin is expressed in 50-60% of metastatic breast cancers while GCDFP-15 is expressed in approximately 20-25%. Mammaglobin is a more sensitive marker than GCDFP-15 for breast carcinoma; however, it lacks the specificity of GCDFP-15. The combination of GCDFP-15 and Mammaglobin and other markers may help to establish the correct interpretation of metastatic breast carcinoma.